Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19
Rachel S Cooper, Alasdair R Fraser, Linda Smith, Paul Burgoyne, Stuart N Imlach, Lisa M Jarvis, David M Turner, Sharon Zahra, Marc L Turner, John D M Campbell, Rachel S Cooper, Alasdair R Fraser, Linda Smith, Paul Burgoyne, Stuart N Imlach, Lisa M Jarvis, David M Turner, Sharon Zahra, Marc L Turner, John D M Campbell
Abstract
COVID-19 disease caused by the SARS-CoV-2 virus is characterized by dysregulation of effector T cells and accumulation of exhausted T cells. T cell responses to viruses can be corrected by adoptive cellular therapy using donor-derived virus-specific T cells. One approach is the establishment of banks of HLA-typed virus-specific T cells for rapid deployment to patients. Here we show that SARS-CoV-2-exposed blood donations contain CD4 and CD8 memory T cells which recognize SARS-CoV-2 spike, nucleocapsid and membrane antigens. Peptides of these antigens can be used to isolate virus-specific T cells in a GMP-compliant process. The isolated T cells can be rapidly expanded using GMP-compliant reagents for use as an allogeneic therapy. Memory and effector phenotypes are present in the selected virus-specific T cells, but our method rapidly expands the desirable central memory phenotype. A manufacturing yield ranging from 1010 to 1011 T cells can be obtained within 21 days culture. Thus, multiple therapeutic doses of virus-specific T cells can be rapidly generated from convalescent donors for potential treatment of COVID-19 patients.
Keywords: CD4; CD8; COVID-19; T cell; adoptive T cell immunotherapy; memory T cell.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2021 Cooper, Fraser, Smith, Burgoyne, Imlach, Jarvis, Turner, Zahra, Turner and Campbell.
Figures
References
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Si HR, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature (2020) 579:270–3. 10.1038/s41586-020-2012-7
- Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature (2020) 579:265–9. 10.1038/s41586-020-2008-3
- COVID-19 situation update worldwide, as of 17th November 2020 (European Centre for Disease Prevention and Control, Situation updates on COVID-19). Available at: .
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan. JAMA (2020) 323:1061–9. 10.1001/jama.2020.1585
- Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. for the COVID-19 Lombardy ICU Network, Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA (2020) 323:1574–81. 10.1001/jama.2020.5394
- Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe COVID-19. N Engl J Med (2020) 382:2327–36. 10.1056/NEJMc2015312
- Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. N Engl J Med (2020). 10.1056/NEJMoa2021436.
- Available at: (Accessed 23rd July 2020).
- Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol (2020) 17:533–5. 10.1038/s41423-020-0402-2
- Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis (2020) 71:762–8. 10.1093/cid/ciaa248
- Garcia LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol (2020) 11:1441. 10.3389/fimmu.2020.01441
- Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol (2020) 20:363–74. 10.1038/s41577-020-0311-8
- Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol (2020) 20:269–70. 10.1038/s41577-020-0308-3
- Manjili RH, Zarei M, Habibi M, Manjili MH. COVID-19 as an acute inflammatory disease. J Immunol (2020) 205:12–9. 10.4049/jimmunol.2000413
- Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol (2020) 215:108448. 10.1016/j.clim.2020.108448
- Campbell JDM, Foerster A, Lasmanowicz V, Niemöller M, Scheffold A, Fahrendorff M, et al. Rapid detection, enrichment and propagation of specific T cell subsets based on cytokine secretion. Clin Exp Immunol (2011) 163:1–10. 10.1111/j.1365-2249.2010.04261.x
- Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood (2004) 103:3565–72. 10.1182/blood-2003-09-3056
- Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol (2006) 134:64–76. 10.1111/j.1365-2141.2006.06108.x
- Kazi S, Mathur A, Wilkie G, Cheal K, Battle R, McGowan N, et al. Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease. Haematologica (2019) 104:e356–9. 10.3324/haematol.2018.207548
- Tzannou I, Watanabe A, Naik S, Daum R, Kuvalekar M, Leung KS, et al. “Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Adv (2019) 3:2571–80. 10.1182/bloodadvances.2019000371
- Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, et al. Allogeneic cytotoxic T-cell therapy for EBV positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood (2007) 110:1123–31. 10.1182/blood-2006-12-063008
- Kiyotani K, Toyoshima Y, Nemoto K, Nakamura Y. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2. J Hum Genet (2020) 65:569–75. 10.1038/s10038-020-0771-5
- Sepulveda CA, Richman SJ, Kaur I, Shen A, Khorana S, O’Connor SL, et al. Evaluation of an Automated Ficoll Procedure to Enrich for Mononuclear Cells for Use in Clinical Trials. Blood (2007) 110:1216. 10.1182/blood.V110.11.1216.1216
- Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine (2020) 55:102763. 10.1016/j.ebiom.2020.102763
- Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun (2020) 11:3410. 10.1038/s41467-020-17240-2
- Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest (2020) 130:2620–9. 10.1172/JCI137244
- Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ. Aging and innate immune cells. J Leukoc Biol (2004) 76:291–9. 10.1189/jlb.1103592
- Overgaard NH, Jung JW, Steptoe RJ, Wells JW. CD4+/CD8+ double-positive T cells: more than just a developmental stage? J Leukoc Biol (2015) 97:31–8. 10.1189/jlb.1RU0814-382
- Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell (2020) 183(1):158–68.e14. 10.1016/j.cell.2020.08.017
- Grifoni A, Weiskopf D, Ramirez S, II, Mateus J, Dan JM, Rydyznski Moderbacher C, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell (2020) 181:1489–501. 10.1016/j.cell.2020.05.015
- Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature (2020) 587(7833):270–4. 10.1038/s41586-020-2598-9
- Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. Nat Immunol (2020) 21(11):1336–45. 10.1038/s41590-020-0782-6
- Zuo J, Dowell A, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection. BioRxiv (2020). 10.1101/2020.11.01.362319
- De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun (2020) 11:3434. 10.1038/s41467-020-17292-4
- Keller MD, Harris KM, Jensen-Wachspress MA, Kankate V, Lang H, Lazarski CA, et al. SARS-CoV-2 specific T-cells Are Rapidly Expanded for Therapeutic Use and Target Conserved Regions of Membrane Protein. Blood (2020) blood.2020008488. 10.1182/blood.2020008488
- Channappanavar R, Fett C, Zhao J, Meyerholx DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol (2014) 88:11034–44. 10.1128/JVI.01505-14
- Kang CK, Han GC, Kim M, Kim G, Shin HM, Song KH, et al. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity. Int J Infect Dis (2020) 97:313–21. 10.1016/j.ijid.2020.05.106
- Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol (2019) 12:13. 10.1186/s13045-019-0701-1
- Chakupurakal G, Onion D, Bonney S, Cobbold M, Mautner V, Moss P. HLA-Peptide Multimer Selection of Adenovirus-specific T Cells for Adoptive T-Cell Therapy. J Immunother (2013) 36:423–31. 10.1097/CJI.0b013e3182a8029e
- Bacher P, Jochheim-Richter A, Mockel-Tenbrink N, Kniemeyer O, Wingenfeld E, Alex R, et al. Clinical-scale isolation of the total Aspergillus fumigatus-reactive T-helper cell repertoire for adoptive transfer. Cytotherapy (2015) 17(10):1396–405. 10.1016/j.jcyt.2015.05.011
- Leung W, Soh TG, Linn YC, Low JG, Loh J, Chan M, et al. Rapid production of clinical-grade SARS-CoV-2 specific T cells. Adv Cell Gene Ther (2020) 31:e101. 10.1002/acg2.101
- Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, et al. Celyad’s novel CAR T-cell therapy for solid malignancies. Curr Res Transl Med (2018) 66(2):53–6. 10.1016/j.retram.2018.03.001
- Mathew D, Giles JR, Baxter AE, Greenplate AR, Wu JE, Alanio C, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science (2020) 369(6508):eabc8511. 10.1126/science.abc8511
- Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Neflore A, et al. Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2. J Virol (2020) 94:e00510–20. 10.1128/JVI.00510-20
- Cooper RS, Fraser AR, Smith L, Burgoyne P, Imlach SN, Jarvis LM, et al. Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19. bioRixv. 10.1101/2020.08.05.23786
Source: PubMed